Biologics in Rheumatology: New Developments, Clinical Uses and Health Implications

$310.00

Coziana Ciurtin, PhD and David A. Isenberg (Editors)
Consultant Rheumatologist, University College London, Department of Rheumatology, London, UK

Series: New Developments in Medical Research
BISAC: MED083000

Significant progress has been acquired in the treatment of rheumatic conditions with the introduction of biologic therapies, which has enabled better control of disease activity and improved patients’ long-term outcome. Apart from several biologic treatments already licensed for use in autoimmune rheumatic conditions, numerous other agents are currently under investigation. This rapid expansion of the therapeutic armamentarium requires a critical analysis of individual biologic options and their clinical indications, in order to facilitate the optimal use of these new therapies. The authors felt that a comprehensive book revisiting all the evidence available regarding the efficacy, cost-effectiveness and health implications of the use of biologics in rheumatology was needed in order to integrate the clinical, ethical and socio-economic aspects related to their use. This book is aimed at specialist doctors, trainees, nurses and health professionals working in the field of rheumatology. It critically appraises the level of evidence behind the use of biologic agents in diverse autoimmune diseases, comprising separate chapters which focus on rheumatoid arthritis, systemic lupus erythematosus, myositis, systemic sclerosis, Sjogren’s syndrome, seronegative spondyloarthropathies, psoriatic arthritis and psoriasis, small, medium and large vessel vasculitis, osteoporosis, and interstitial lung disease associated with rheumatic conditions. In addition, the book explores aspects related to the use of biologic agents, such as ethical considerations of consenting patients to take part in clinical trials with biologics, and adolescent and adult rheumatology nurse perspectives related to patients’ benefits of biologic therapies. Particular interest is given to the use of biologics during pregnancy and assessment of their infectious risks. A separate chapter explores the off-target benefits associated with the use of anti-TNF therapies. Several chapters include data about cost-effectiveness, and national and international guidelines for the use of biologic agents in different rheumatic conditions. (Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Preface

Biological Treatments in Autoimmune Rheumatic Diseases

Chapter 1. Biologic Therapies for Systemic Lupus Erythematosus
Maria Mouyis, Coziana Ciurtin and David A. Isenberg (Northwick Park University Hospital, London, UK, and others)

Chapter 2. Biologics in Juvenile Systemic Lupus Erythematosus
Claire-Louise Murphy and Nicola Ambrose (University College London Hospital, London, UK)

Chapter 3. Biologic Treatments for Idiopathic Inflammatory Myopathies
Serena Fasano and David A. Isenberg (Second University of Naples, Naples, Italy)

Chapter 4. Biologic Treatment Advances in Sjӧgren’s Syndrome: Understanding the Implications of using Biologic Therapies in Selected Categories of Patients
Coziana Ciurtin, Nicolyn Thompson and David A. Isenberg (University College London, London, UK)

Chapter 5. Biologic Therapies in Systemic Sclerosis
Svetlana Nihtyanova and Christopher P. Denton (UCL Medical School, Royal Free Campus, London, UK)

Chapter 6. The Role of Biologics in the Treatment of Small and Medium Vessel Vasculitis
Lubna Ghani and Eleana Ntatsaki (Royal Free Hospital, London, UK, and others)

Chapter 7. Imaging and Pathogenesis in Large Vessel Vasculitis: Early Lessons for Biologic Treatments
Philip P. Stapleton, Katerina Achilleos, Dimos Merinopoulos, and Bhaskar Dasgupta (Southend University Hospital, Essex, UK)

Chapter 8. Biologics in Behçet Syndrome
Emon Khan (University College London, London, UK)

Biologic Treatments in Chronic Inflammation Arthritides

Chapter 9. Tumour Necrosis Factor Inhibitors used in the Treatment of Rheumatoid Arthritis: Evidence of Safety, Efficacy and Health Implication
Laura Attipoe, Katie Bechman and Coziana Ciurtin (University College London Hospital, London, UK, and others)

Chapter 10. Biologic Treatments (Other than Anti-TNF Therapy) Licensed for Use in Rheumatoid Arthritis
Laura Attipoe, Katie Bechman and Coziana Ciurtin (University College London Hospital, London, UK, and others)

Chapter 11. New Biologic Agents and Biosimilars Developed for Rheumatoid Arthritis
Laura Attipoe, Katie Bechman and Coziana Ciurtin (University College London Hospital, London, UK, and others)

Chapter 12. Biologics in Spondyloarthritis
Mediola Ismajli and Maria Leandro (University College London Hospital, London, UK)

Chapter 13. Established and New Biologic Therapies for Psoriatic Arthritis and Psoriasis
Benjamin J Thomas, Sarah Elyoussi and Coziana Ciurtin (UCL Medical School, London, UK, and others)

Chapter 14. Biologics in Juvenile Idiopathic Arthritis
Charalampia Papadopoulou and Nicola Ambrose (Institute of Child Health, UCL, London, UK, and others)

Miscellanea

Chapter 15. Biologic Disease Modifying Anti-Rheumatic Drugs in Pregnancy and Breast-Feeding Period
Hanh Nguyen and Ian Giles (University College London, London, UK)

Chapter 16. Biologic Therapy in Osteoporosis: New Developments, Clinical uses and Health Implications
Maria Mouyis and Judith Bubbear (Northwick Park Hospital, London, UK, and others)

Chapter 17. Biologic Treatments for Pulmonary Involvement in Rheumatic Disease
Helen S. Garthwaite and Joanna C. Porter (University College London, London, UK)

Chapter 18. Additional Benefits of Tumour Necrosis Factor Inhibitor Therapies
Angela Pakozdi and Vanessa Morris (University College London, London, UK)

Chapter 19. Infection and Biologics
Maria Krutikov and Jessica Manson (University College London, London, UK)

Chapter 20. Participant Information Sheets in Clinical Research: Compromising the Ethics of Informed Consent?
Andra Negoescu, and Leslie Gelling (Addenbrooke’s Hospital, Cambridge, UK, and others)

Chapter 21. Biologic Treatment: The Young Patients’ Perspective
Nicola Daly (University College London, London, UK)

Chapter 22. Strategies and Safety Nets: Nurse-Led Care of the Patient on Biologics
Pauline Buck and Victoria Howard (University College London, London, UK)

Index


The book is aimed at specialist doctors, trainees, nurses and health professionals working in the field of rheumatology.

Additional information

Binding

,